The company Medical Pharmaquality, after its successful course in the Greek pharmaceutical market this year, in which it introduced 10 generic drugs, announces its collaboration with the Italian pharmaceutical company Chiesi.
Source:http://www.ygeianews.gr/section/farmaka/content/sunergasia-tis-chiesi-me-tin-medical-pharmaquality
The company Medical Pharmaquality, after its successful course in the Greek pharmaceutical market this year, in which it introduced 10 generic drugs, announces its collaboration with the Italian pharmaceutical company Chiesi.
Chiesi was founded in 1935 with headquarters in Parma and now has subsidiaries in 24 countries, including Greece. Medical Pharmaquality was founded in March 2011 and is a Greek company.
As of 1 June 2012, Medical Pharmaquality assumes the responsibility for the Italian information on Chiesi’s Brexin product. With this collaboration, Medical Pharmaquality, having achieved its first strategic goal of growth, i.e. engaging in the generic product market, is advancing to the next which is collaborating with Research Companies and original products.
We believe that this collaboration will be another great success of Medical Pharmaquality in the Greek pharmaceutical market.
BREXIN
Brexin is the original research and development product of Chiesi. The molecule of its active substance is innovative as it is a complex of β-cyclodextrine and piroxicam. Brexin is a rapid and effective NSAID, suitable to treat pain and inflammation in acute and chronic musculoskeletal disorders.
